[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343087-105":59,"doc-detail-343087-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unlocking-the-potential-of-hhla2-identifying-functional-immune-infiltrating-cells-in-the-tumor-microenvironment-and-predicting-clinical-outcomes-in-laryngeal-squamous-cell-carcinoma","Unlocking the potential of HHLA2 - identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma","","HHLA2 is a newly identified member of the B7 immune checkpoint family, showing limited normal tissue expression but frequent overexpression across cancers. Its precise immune-cell functions and interactions, particularly in laryngeal squamous cell carcinoma (LSCC), remain unclear. Multiplex immunohistochemistry of LSCC tissue microarrays (n=72) assessed HHLA2 expression and multiple immune infiltrating populations, then evaluated associations with overall survival using Kaplan–Meier and COX regression analyses. HHLA2 expression correlated with poorer survival and remained an independent prognostic factor in multivariate analysis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unlocking-the-potential-of-hhla2-identifying-functional-immune-infiltrating-cells-in-the-tumor-microenvironment-and-predicting-clinical-outcomes-in-laryngeal-squamous-cell-carcinoma/343087/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unlocking-the-potential-of-hhla2-identifying-functional-immune-infiltrating-cells-in-the-tumor-microenvironment-and-predicting-clinical-outcomes-in-laryngeal-squamous-cell-carcinoma/343087.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is HHLA2 and why is it studied in LSCC?","Question",{"text":112,"@type":113},"HHLA2 is a B7 immune checkpoint member with limited normal tissue expression but notable overexpression in cancers. The study investigates its biological role and clinical relevance in LSCC tumor microenvironments.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were immune cells and HHLA2 expression measured?",{"text":117,"@type":113},"The study used multiplexed immunohistochemistry on tissue microarrays from LSCC patients (n=72) to quantify HHLA2 and multiple immune populations, including macrophage subsets and CTLA-4/PD-1/LAG-3/TIM-3 related T-cell subsets.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the survival analyses show?",{"text":121,"@type":113},"Higher HHLA2 expression was significantly associated with worse overall survival in LSCC. Multivariate COX analysis identified HHLA2 as an independent predictive factor for overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343087,1790211911,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Immunology, Immunotherapy (2024) 73:207 [https://doi.org/10.1007/s00262-024-03791-6](https://doi.org/10.1007/s00262-024-03791-6)  \nUnlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma  \nWenjing Li1,2 · Jianqing You1 · Haixiang Xue1 · Yi Liu2,3,4 · Junjun Chen2,3,4 · Xiao Zheng2,3,4 · Lujun Chen2,3,4 · Changping Wu2,3,4  \nReceived: 20 June 2024 / Accepted: 23 July 2024 / Published online: 6 August 2024 © The Author(s) 2024  \nAbstract  \nBackground HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC) . This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis.  \nMethods Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68+HLA-DR+CD163 − (M1 macrophages), CTLA-4+CD4+FoxP3+ (CTLA-4+Treg cells), CTLA-4+CD4+FoxP3 − (CTLA- 4+Tcon cells), exhausted CD8+T cells, and terminally exhausted CD8+T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors.  \nResults Kaplan–Meier (K–M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3 .230, 95%CI 0 .9205–11.34, P = 0.0067) . Notably, increased infiltration of CD68+ cells (total macrophages), STING+CD68+HLA-DR+CD163 − (STING+M1 macrophages), CTLA-4+CD4+FoxP3+, CTLA-4+CD4+FoxP3 − , PD-1+LAG-3+CD8+T cells, and PD-1+LAG-3+TIM-3+CD8+T cells strongly linked to poorer survival outcomes (P \u003C 0 .05) . A discernible trend was observed between the levels of these immune cell populations, STING+CD68+ (STING+ total macrophages), CD68+HLA-DR+CD163 − , STING+CD68+CD163+HLA-DR − (STING+M2 macrophages), PD-1+LAG-3 − CD8+T cells, PD-1+TIM-3+CD8+T cells, and PD-1+LAG-3+TIM-3 − CD8+T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08–13.80, P = 0.038). This underscored the potential of HHLA2 as a critical marker for predicting patient outcomes in LSCC. Conclusions HHLA2 emerged as a detrimental prognostic biomarker for assessing OS in LSCC patients. Relative to other immune checkpoints, HHLA2 exhibited heightened predictive efficacy for the prognosis of LSCC patients.  \nKeywords Laryngeal squamous cell carcinoma · HHLA2 · Immune infiltrating cell · Prognosis  \nIntroduction  \nLaryngeal cancer, the second most common malignancy in the respiratory system after lung cancer, exhibits a high mortality rate and a notably elevated incidence among  \nExtended author information available on the last page of the article  \nhead-and-neck tumors [1] . Squamous cell carcinoma is the predominant histological subtype [2] . Despite therapeutic advancements leading to a 5-year overall survival (OS) rate approaching 50%, over 40% of patients with laryngeal squamous cell carcinoma (LSCC) are typically diagnosed at an advanced stage [3, 4]. Currently, there is a significant lack of predictive tools to assess the progression of LSCC.  \nRecent studies ha","cbCaianfdokROHxw","https://ap.wps.com/l/cbCaianfdokROHxw","pdf",2092779,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is HHLA2 and why is it studied in LSCC?\",\"answer\":\"HHLA2 is a B7 immune checkpoint member with limited normal tissue expression but notable overexpression in cancers. The study investigates its biological role and clinical relevance in LSCC tumor microenvironments.\"},{\"question\":\"How were immune cells and HHLA2 expression measured?\",\"answer\":\"The study used multiplexed immunohistochemistry on tissue microarrays from LSCC patients (n=72) to quantify HHLA2 and multiple immune populations, including macrophage subsets and CTLA-4/PD-1/LAG-3/TIM-3 related T-cell subsets.\"},{\"question\":\"What did the survival analyses show?\",\"answer\":\"Higher HHLA2 expression was significantly associated with worse overall survival in LSCC. Multivariate COX analysis identified HHLA2 as an independent predictive factor for overall survival.\"}]","Unlocking the potential of HHLA2 - identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma | PDF",1790049821,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a20841428dc54b044758f6b2b56ade2c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a194ea78b2da97a935086365987cbbd4.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef60647454ed1f72ec7ffce4a7c99bf1.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/617811dddcffd96a581f2d9d54bb248a.webp",980,1301]